Psychotic Disorder Treatment

Worldwide Revenue From Psychotic Disorder Treatment To Increase At A High CAGR Of 6.1% Between 2022 And 2032

Healthcare

Psychotic Disorder Treatment Market Outlook (2022-2032)

At present, the global psychotic disorder treatment market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.

Stress levels among the general population have increased notably over the past few years and this has led to an increase in the incidence of psychotic disorders such as bipolar disorder, schizophrenia, etc.

Fact.MR forecasts worldwide revenue from psychotic disorder treatment to increase at a high CAGR of 6.1% between 2022 and 2032.

Request Sample- https://www.factmr.com/connectus/sample?flag=S&rep_id=568

Segmentation of Psychotic Disorder Treatment Industry Research

  • Psychotic Disorder Treatment Market by Drug Type :

    • Atypical Antipsychotics
    • Phenothiazine Antipsychotics
    • Thioxanthenes
    • Miscellaneous Antipsychotics Agents
  • Psychotic Disorder Treatment Market by Indication :

    • Schizophrenia
    • Bipolar Disorder
    • Delusional Disorder
    • Drug Induced Psychosis
    • Organic Psychosis
  • Psychotic Disorder Treatment Market by Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Store
    • e-Commerce
  • Psychotic Disorder Treatment Market by Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Competitive Landscape

Psychotic disorder treatment providers are pushing for the approval of new drugs and treatment therapies from regulatory bodies to fast-track the launch of these novel treatments.

  • In February 2022, AbbVie, a leading biopharmaceutical organization, announced that it had submitted a Supplemental New Drug Application to the United States Food and Drug Administration (FDA). The application is based on new clinical trial results for cariprazine (VRAYLAR®) for adjunctive treatment of major depressive disorder (MDD).
  • In April 2022, BioXcel Therapeutics, a renowned biopharmaceutical firm, announced that it had received approval for IGALMI™ (dexmedetomidine) Sublingual Film by the U.S. FDA, which will be used to treat bipolar disorder.

Leave a Reply

Related Posts